Description

Zoetis Is Not Just A Companion Animal Story — Livestock Revenue Jumps 11%!

Zoetis, Inc. reported second-quarter 2026 results reflecting a difficult operating environment, particularly in U.S. Companion Animal. Global revenue was $2.5 billion, flat on a reported basis and down 1% organically. Adjusted net income declined 2% organically, with international revenue rising 6% and U.S. revenue falling 7%. Livestock revenue increased 11% globally, supported by strong cattle and poultry demand, while Companion Animal revenue declined 6%, mainly due to weakness in Dermatology and parasiticides. U.S. Companion Animal revenue fell 11% as veterinary clinic visits continued to decline and pet owners became more selective about spending amid veterinary price increases that have often exceeded consumer inflation. Dermatology revenue declined 16% globally and 18% in the U.S., reflecting fewer clinic visits for canine pruritic conditions and greater competition, discounting, and promotional activity. Zoetis retained approximately 86% U.S. in-clinic Dermatology market share, although this declined sequentially.